- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00712907
Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow
High arterial blood oxygen tension leads to vasoconstriction of retinal vessels, possibly related to an interaction between reactive oxygen species and endothelium-derived vasoactive factors. Vitamin C is a potent antioxidant capable of reversing endothelial dysfunction due to increased oxidant stress. Vitamin C appears to have vasodilatory properties, but the underlying mechanisms are not well understood.
In the present study we hypothesized that hyperoxic vasoconstriction of retinal vessels could be diminished by vitamin C.
Ocular blood flow will be determined by non-invasive methods, including laser Doppler velocimetry and the Zeiss retinal vessel analyser.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Department of Clinical Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men aged between 19 and 35 years, nonsmokers
- Body mass index between 15th and 85th percentile (Must A 1991)
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
- Normal ophthalmic findings, ametropia < 3 Dpt.
Exclusion Criteria:
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Treatment in the previous 3 weeks with any drug
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with, distribution, metabolism or excretion of study drugs
- Blood donation during the previous 3 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day. Dosage reference: Strenn K 1997
Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v.
Dosage: 24ml/min over 64 min
|
Active Comparator: 1
vitamin C (Mayrhofer)
|
Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v.
Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day. Dosage reference: Strenn K 1997 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Retinal arterial and venous diameter (Zeiss retinal vessel analyzer)
Time Frame: in total 6 hours
|
in total 6 hours
|
Retinal blood flow velocity (laser Doppler velocimetry)
Time Frame: in total 6 hours
|
in total 6 hours
|
Intraocular pressure (applanation tonometry)
Time Frame: in total 10 minutes
|
in total 10 minutes
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPHT-161202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Physiology
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
Nidek Co. LTD.CompletedOcular PhysiologyUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedOcular PhysiologyUnited States
-
Medical University of ViennaWithdrawn
-
Medical University of ViennaCompletedOcular Physiology | MicrocirculationAustria
-
Medical University of ViennaWithdrawnIntraocular Pressure | Ocular PhysiologyAustria
-
Medical University of ViennaCompletedOcular Physiology | Regional Blood FlowAustria
-
Medical University of ViennaCompletedOcular Physiology | Regional Blood FlowAustria
Clinical Trials on vitamin C (Mayrhofer) 24mg/min i.v. for 64 min
-
Maastricht University Medical CenterVitaKUnknownCoronary Artery DiseaseNetherlands
-
Massachusetts General HospitalBrigham and Women's Hospital; University of California, San Francisco; Harvard...CompletedInflammation | Atherosclerosis | HIVUnited States
-
Mid-Atlantic Retina Consultations, Inc.West Virginia UniversityUnknownDiabetic Macular Edema | Neovascular Age-related Macular DegenerationUnited States
-
South Plains Oncology ConsortiumTerminatedNon-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaUnited States
-
SanofiCompletedUveitisItaly, Turkey, Spain, United States, Czechia, France
-
St. Jude Children's Research HospitalTerminatedAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
National Cancer Institute (NCI)CompletedUntreated Adult Acute Myeloid Leukemia | Adult Acute Promyelocytic Leukemia (M3) | Childhood Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesUnited States
-
Dana-Farber Cancer InstituteColumbia University; Boston Children's Hospital; McMaster University; University... and other collaboratorsCompleted
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLymphomaUnited States, Puerto Rico
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLeukemiaUnited States